Cargando…
FRI508 A Case Of Durvalumab Induced Hypothyroidism
Disclosure: E.D. Cecilio La Riva: None. C. Acosta: None. A.J. Manzano: None. Background: Immune checkpoint inhibitors (ICIs), like Durvalumab, have become a mainstay in cancer treatment as they have significantly improved survival rates, especially for lung cancer. These treatments, however, have be...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555657/ http://dx.doi.org/10.1210/jendso/bvad114.1854 |